8-K: ImageneBio Changes Auditors to PwC from EY

ImageneBio, Inc. announced the dismissal of Ernst & Young LLP as its independent auditor and the appointment of PricewaterhouseCoopers LLP, effective August 2, 2025.

Summary

• ImageneBio, Inc. (formerly Ikena Oncology, Inc.) dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm, effective August 2, 2025.
• EY's audit reports on ImageneBio's consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion, disclaimer of opinion, or any qualifications.
• No disagreements with EY on accounting principles, practices, financial statement disclosure, or auditing scope or procedure were reported during the fiscal years ended December 31, 2024 and 2023, or the subsequent interim period through August 2, 2025.
• No reportable events, as defined by Regulation S-K, occurred with EY during the specified periods.
• PricewaterhouseCoopers LLP (PwC) was appointed as ImageneBio's new independent registered public accounting firm for the fiscal year ending December 31, 2025, upon approval of the Audit Committee.
• PwC previously served as the independent registered public accounting firm for Inmagene Biopharmaceuticals prior to its merger with ImageneBio.
• ImageneBio did not consult with PwC regarding accounting principles or audit opinions that would constitute a disagreement or reportable event prior to PwC's appointment.

Sentiment

Score: 7

Explanation: The change in auditor is a routine corporate governance matter, especially following a merger. The explicit statement of no disagreements or reportable events with the outgoing auditor, Ernst & Young LLP, indicates a smooth and non-contentious transition, which is a positive sign for corporate governance and financial transparency.

Positives

• Ernst & Young LLP's audit reports for the fiscal years ended December 31, 2024 and 2023 were unqualified, indicating no significant accounting or auditing issues.
• No disagreements or reportable events were reported with the outgoing auditor, Ernst & Young LLP, suggesting a smooth and non-contentious transition.

Future Outlook

No specific forward-looking statements or guidance regarding financial performance or strategic direction were provided beyond the appointment of the new auditor for the fiscal year ending December 31, 2025.

Management Comments

• The report was signed by Kristin Yarema, Ph.D., Chief Executive Officer of ImageneBio, Inc.

Industry Context

Changes in independent registered public accounting firms are common, particularly following significant corporate events such as mergers. The appointment of PricewaterhouseCoopers LLP, which previously audited Inmagene Biopharmaceuticals (the entity that merged with ImageneBio), suggests a consolidation of auditing services to streamline financial reporting post-merger, a standard practice in the biotechnology and pharmaceutical industries.

Comparison to Industry Standards

• This auditor change aligns with common industry practice following a merger, where companies often consolidate auditing firms to streamline financial reporting and leverage existing relationships. For instance, after large pharmaceutical mergers, the combined entity typically selects one auditing firm to oversee all financial statements, similar to how Pfizer consolidated its auditing services after acquiring Wyeth.
• The explicit statement of no disagreements or reportable events with the outgoing auditor, Ernst & Young LLP, is a positive indicator of sound corporate governance and a non-contentious transition, which is a favorable sign compared to situations where auditor changes are driven by disputes over accounting practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides clarity on the company's auditing firm, ensuring continued financial oversight and transparency.
• Management: Streamlines financial reporting processes by consolidating auditing services with a firm familiar with the merged entity's prior operations.

Next Steps

• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

This filing details a routine change in the company's independent registered public accounting firm following a merger, with no reported disagreements or issues with the outgoing auditor. Such a change is a standard corporate governance action and does not provide new information that would fundamentally alter the investment thesis for ImageneBio, Inc. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for significant price movement, either positive or negative.

Keywords

Biotechnology, Pharmaceuticals, Auditor Change, SEC Filing, 8-K, Corporate Governance, ImageneBio, Ernst & Young, PricewaterhouseCoopers